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or previously published work. The algorithm has been subse-
quently further tested on a second cohort2 to assess the reproduc-
ibility of the approach.
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O-23 IMPRINTED GENE METHYLATION IN BLOOD AND RISK OF
BREAST CANCER
P. Haggarty, G. Hoad, P. Scott, L. Simpson, A. Samad, E. Smyth, S.D.
Heys. RINH, University of Aberdeen, Aberdeen, UK
Loss of imprinting is a common observation in tumours but it
is not known whether this results from other pathologies or
whether imprinting changes may predispose to disease. We set
out to determine whether women newly diagnosed with breast
cancer had altered imprinted gene methylation in non-tumour
tissue (blood cells) compared to women without the disease.
Over 1000 women – newly diagnosedwith breast cancer and dis-
ease free controls – were recruited at Aberdeen Breast Clinic. A
sample of 92 controls and 92 cases were matched for age, weight,
height, BMI and menopausal status. Multiple methylation sites
were measured in two imprinted genes (IGF2 and PEG3) in blood
DNA. Methylation was determined by pyrosequencing using a Qia-
gen PyroMark MD system after bisulphite conversion of DNA using
Epitect Bisulfite kits (Qiagen, Crawley, UK). Analysis of variancewas
carried out using STATA 11MP (Stata Corp, College Station, USA).
The mean population methylation level was 47.6 (SD 2.5)% for
PEG3 and 50.0 (SD 5.5)% for IGF2. Compared to controls, women
diagnosed with breast cancer had significantly different levels
of methylation in PEG3 (p < 0.001). IGF2 methylation was also dif-
ferent between groups but this was only approaching statistical
significance (p = 0.058). Methylation was not related to meno-
pausal status. These differences in normal tissue suggest that
altered imprinted gene methylation may precede the develop-
ment of the disease. They also point to early life programming
as a possible cause of breast cancer.
This study was funded by Breast Cancer Campaign (Project
2008MayPR46).
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O-24 INVESTIGATION OF BRCA1 AND BRCA2 UNCLASSIFIED
VARIANTS USING RNA STUDIES: EXPERIENCES AND INTEREST-
ING CASES FROM THE WEST MIDLANDS REGIONAL GENETICS
LABORATORY
Elizabeth Perrott, Pauline K. Rehal, Ana Maria Brasgoldberg,
Fiona Macdonald. West Midlands Regional Genetics Laboratory,
Birmingham, UK
A very successful high throughput screening strategy for the
BRCA1 and BRCA2 genes has now been established at the West
Midlands Regional Genetics laboratory (WMRGL) since 2006. How-
ever having resolved the problems of large backlogs and long
reporting times the challenge has now shifted to the prediction
of the functional consequence of variants of unknown clinical
significance which account for a significant proportion of
reported sequence alterations in BRCA1 and BRCA2.
Laboratory methods to identify which of these sequence vari-
ants are pathogenic mutations would have utility for counseling
and clinical decision making when identified in patients with a
family history of breast cancer.
The WMRGL currently undertakes RNA investigations on
unclassified sequence variants for several familial cancer disor-
ders for both local and external referrals. To date we have under-
taken analysis on 92 cases covering 13 different disorders
including non-cancers. RNA investigations specifically for BRCA1
or BRCA2 variants have been performed on 25 samples. An over-
view of the service will be presented together with results from
interesting cases highlighting the challenges faced in interpreta-
tion of this data.
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O-25 ER POSITIVE SCREEN DETECTED BREAST CANCERS (SDBC)
DO NOT REQUIRE CHEMOTHERAPY
N.J. Bundred a, J. Morris b, S. Cheung c, W.F. Knox d, G.M.
Lawrence c. aAcademic Department of Surgery, University Hospital of
South Manchester, UK. bAcademic Department of Statistics, University
Hospital of South Manchester, UK. cWest Midlands Cancer Intelligence
Unit, Birmingham, UK. dAcademic Department of Pathology, University
Hospital of South Manchester, UK
Meta-analysis of symptomatic breast cancer trials advises
chemotherapy to women <70 years of age at high risk of death
(i.e. benefit of >1% survival benefit from treatment) but UK screen
detected breast cancers (SDBC) (aged 50–65 years) have an overall
97.2% 5 year relative survival compared to 77.6% for symptomatic
cancers. Guidelines recommend chemotherapy for all cancers
>10 mm in size (i.e. 35% SDBC) whereas in 2001/2 only 23% SDBC
in the UK received chemotherapy.
To determine which women benefit from chemotherapy, we
analysed 1681 symptomatic and SDBC in Manchester. SDBC had
a lower risk of relapse with 5 year cancer mortality for oestro-
gen receptor (ER) positive cancers being low in the Excellent
(0%), Good (GPG) (1%) and Moderate Prognostic Group 1
(MPG1) (4%) but higher in the symptomatic GPG (4.1%) and
MPG1 (15.5%) (p 6 0.001). The ABS at BASO Audit 2001/2 indi-
cates 5 year survival improvements in the Moderate Prognostic
Group 2 (MPG2) and the Poor Prognostic Group (PPG) for SDBC
since 1990.
ER positive SDBC had a <0.6% mortality annually whereas the
symptomatic cancers had a 5% annual mortality in the first
5 years. ER positive SDBCs represent a group with a low risk of
relapse, not requiring chemotherapy. Improvements in survival
of SDBC relate to better treatment of ER negative and HER2
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